Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Eiger Biopharmaceuticals (EIGRQ) is now available.
Eiger BioPharmaceuticals, Inc. and its subsidiaries, currently in Chapter 11 bankruptcy, have submitted their Monthly Operating Reports for May 2024 to the court, cautioning investors about their speculative nature and warning against using them for investment decisions. These reports, which are not GAAP-compliant, may be subject to change and do not reflect a comprehensive financial picture. The company stresses the high risk involved in trading its securities during bankruptcy proceedings and reminds stakeholders of the potential for significant or complete investment loss, depending on the case outcome. Additionally, forward-looking statements included in the reports are speculative and not guaranteed, with the company’s future being uncertain and subject to various risks.
For an in-depth examination of EIGRQ stock, go to TipRanks’ Stock Analysis page.
